UA77809C2 - Tricyclic spiropiperidines or spiropyrrolidines, method for their synthesis (variants), use thereof, method for treating inflammations and respiratory diseases, pharmaceutical composition, intermediate, method for producing intermediate - Google Patents

Tricyclic spiropiperidines or spiropyrrolidines, method for their synthesis (variants), use thereof, method for treating inflammations and respiratory diseases, pharmaceutical composition, intermediate, method for producing intermediate Download PDF

Info

Publication number: UA77809C2
Authority: UA; Ukraine
Prior art keywords: spiro; benzofuran; chloro; oxy; hydroxypropyl
Prior art date: 2002-07-08

Application number

UA20041210166A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-08

Filing date

2003-07-07

Publication date

2007-01-15

2003-07-07 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2007-01-15 Publication of UA77809C2 publication Critical patent/UA77809C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 33
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
230000015572 biosynthetic process Effects 0.000 title claims description 19
238000004519 manufacturing process Methods 0.000 title claims description 8
206010061218 Inflammation Diseases 0.000 title 1
230000004054 inflammatory process Effects 0.000 title 1
208000023504 respiratory system disease Diseases 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 305
238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 297
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 168
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 165
-1 cyano, hydroxyl Chemical group 0.000 claims description 109
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 86
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 85
229910052757 nitrogen Inorganic materials 0.000 claims description 72
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 69
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 64
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 63
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 62
METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 57
JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims description 55
125000001424 substituent group Chemical group 0.000 claims description 54
229910052736 halogen Inorganic materials 0.000 claims description 47
150000002367 halogens Chemical class 0.000 claims description 47
125000000623 heterocyclic group Chemical group 0.000 claims description 46
229920006395 saturated elastomer Polymers 0.000 claims description 43
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
229910052760 oxygen Inorganic materials 0.000 claims description 38
150000003839 salts Chemical class 0.000 claims description 38
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 37
239000001301 oxygen Chemical group 0.000 claims description 37
239000012453 solvate Substances 0.000 claims description 37
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 36
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 35
125000005842 heteroatom Chemical group 0.000 claims description 34
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 33
229910052717 sulfur Chemical group 0.000 claims description 33
239000011593 sulfur Chemical group 0.000 claims description 33
LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims description 32
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 31
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 30
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 29
229910052731 fluorine Inorganic materials 0.000 claims description 25
239000011737 fluorine Substances 0.000 claims description 24
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 23
239000002253 acid Substances 0.000 claims description 23
239000004202 carbamide Substances 0.000 claims description 23
239000000460 chlorine Substances 0.000 claims description 22
239000005711 Benzoic acid Substances 0.000 claims description 21
125000000217 alkyl group Chemical group 0.000 claims description 21
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
229910052801 chlorine Inorganic materials 0.000 claims description 21
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 19
125000004122 cyclic group Chemical group 0.000 claims description 18
HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims description 18
235000010233 benzoic acid Nutrition 0.000 claims description 17
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 15
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
125000004043 oxo group Chemical group O=* 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 11
125000006413 ring segment Chemical group 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
BBWJIHMTJCJDKJ-UHFFFAOYSA-N 1,2-oxazolidin-4-ol Chemical compound OC1CNOC1 BBWJIHMTJCJDKJ-UHFFFAOYSA-N 0.000 claims description 8
BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 claims description 8
IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 7
229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 7
125000003368 amide group Chemical group 0.000 claims description 7
229910052796 boron Inorganic materials 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
125000001188 haloalkyl group Chemical group 0.000 claims description 7
125000004430 oxygen atom Chemical group O* 0.000 claims description 7
QXSAKPUBHTZHKW-UHFFFAOYSA-N 4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 claims description 6
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 6
208000006673 asthma Diseases 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 claims description 5
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
125000006239 protecting group Chemical group 0.000 claims description 5
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 5
GKTFLKJXZOYBRW-UHFFFAOYSA-N 2-ethylbenzamide Chemical compound CCC1=CC=CC=C1C(N)=O GKTFLKJXZOYBRW-UHFFFAOYSA-N 0.000 claims description 4
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 claims description 4
125000005059 halophenyl group Chemical group 0.000 claims description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-M serinate Chemical compound OCC(N)C([O-])=O MTCFGRXMJLQNBG-UHFFFAOYSA-M 0.000 claims description 4
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 4
102000009410 Chemokine receptor Human genes 0.000 claims description 3
108050000299 Chemokine receptor Proteins 0.000 claims description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
230000000694 effects Effects 0.000 claims description 3
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
KGGHWIKBOIQEAJ-UHFFFAOYSA-N 2-fluorobenzamide Chemical compound NC(=O)C1=CC=CC=C1F KGGHWIKBOIQEAJ-UHFFFAOYSA-N 0.000 claims description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
239000010949 copper Substances 0.000 claims description 2
208000027866 inflammatory disease Diseases 0.000 claims description 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
RSCLTAHCZHPGHS-UHFFFAOYSA-N pyrrolidin-3-yl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1CCNC1 RSCLTAHCZHPGHS-UHFFFAOYSA-N 0.000 claims description 2
IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 claims description 2
238000007363 ring formation reaction Methods 0.000 claims description 2
230000003993 interaction Effects 0.000 claims 5
INTCGJHAECYOBW-APWZRJJASA-N (2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-ol Chemical compound C([C@](O)([C@@H](CN(C)C)C)C=1C=CC=CC=1)C1=CC=CC=C1 INTCGJHAECYOBW-APWZRJJASA-N 0.000 claims 1
KPGSFHSKMGACKM-UHFFFAOYSA-N 2-(2-methylpropyl)benzamide Chemical compound CC(C)CC1=CC=CC=C1C(N)=O KPGSFHSKMGACKM-UHFFFAOYSA-N 0.000 claims 1
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 claims 1
235000002566 Capsicum Nutrition 0.000 claims 1
239000006002 Pepper Substances 0.000 claims 1
235000016761 Piper aduncum Nutrition 0.000 claims 1
235000017804 Piper guineense Nutrition 0.000 claims 1
244000203593 Piper nigrum Species 0.000 claims 1
235000008184 Piper nigrum Nutrition 0.000 claims 1
208000018569 Respiratory Tract disease Diseases 0.000 claims 1
230000009286 beneficial effect Effects 0.000 claims 1
WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 claims 1
WPYMKLBDIGXBTP-VQEHIDDOSA-N benzoic acid Chemical compound OC(=O)C1=CC=C[13CH]=C1 WPYMKLBDIGXBTP-VQEHIDDOSA-N 0.000 claims 1
235000010290 biphenyl Nutrition 0.000 claims 1
239000004305 biphenyl Substances 0.000 claims 1
229910052802 copper Inorganic materials 0.000 claims 1
OJEYDZBIAYMFFD-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1C[CH]CC1 OJEYDZBIAYMFFD-UHFFFAOYSA-N 0.000 claims 1
125000004050 enoyl group Chemical group 0.000 claims 1
ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims 1
BAULSHLTGVOYKM-UHFFFAOYSA-N n-butylbenzamide Chemical compound CCCCNC(=O)C1=CC=CC=C1 BAULSHLTGVOYKM-UHFFFAOYSA-N 0.000 claims 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 1
229960002368 travoprost Drugs 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 489
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 368
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 348
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 220
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 187
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 177
239000000203 mixture Substances 0.000 description 155
239000011541 reaction mixture Substances 0.000 description 149
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 136
229910002027 silica gel Inorganic materials 0.000 description 129
239000000741 silica gel Substances 0.000 description 129
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 125
238000003818 flash chromatography Methods 0.000 description 124
235000019439 ethyl acetate Nutrition 0.000 description 117
238000005481 NMR spectroscopy Methods 0.000 description 113
239000000243 solution Substances 0.000 description 112
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 94
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 92
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 92
239000000908 ammonium hydroxide Substances 0.000 description 92
229910052938 sodium sulfate Inorganic materials 0.000 description 92
235000011152 sodium sulphate Nutrition 0.000 description 92
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 90
239000012044 organic layer Substances 0.000 description 88
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 82
238000005160 1H NMR spectroscopy Methods 0.000 description 73
239000003039 volatile agent Substances 0.000 description 72
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 66
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 60
FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 52
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 47
238000003756 stirring Methods 0.000 description 44
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 41
238000010992 reflux Methods 0.000 description 40
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 39
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 34
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
239000000047 product Substances 0.000 description 27
239000002904 solvent Substances 0.000 description 25
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 24
239000007787 solid Substances 0.000 description 24
238000004128 high performance liquid chromatography Methods 0.000 description 22
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 21
229910000024 caesium carbonate Inorganic materials 0.000 description 21
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 21
239000003208 petroleum Substances 0.000 description 21
239000000725 suspension Substances 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 19
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 18
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 18
239000003921 oil Substances 0.000 description 18
235000019198 oils Nutrition 0.000 description 18
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 17
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 17
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 16
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 16
229910052740 iodine Inorganic materials 0.000 description 16
239000011630 iodine Substances 0.000 description 16
239000010410 layer Substances 0.000 description 16
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 16
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 16
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
235000017557 sodium bicarbonate Nutrition 0.000 description 14
229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
239000000284 extract Substances 0.000 description 13
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 12
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
229910052794 bromium Inorganic materials 0.000 description 12
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
238000000746 purification Methods 0.000 description 11
239000012265 solid product Substances 0.000 description 11
125000004453 alkoxycarbonyl group Chemical group 0.000 description 10
238000009835 boiling Methods 0.000 description 10
239000012074 organic phase Substances 0.000 description 10
206010039083 rhinitis Diseases 0.000 description 10
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 9
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 9
239000007864 aqueous solution Substances 0.000 description 9
238000001704 evaporation Methods 0.000 description 9
230000008020 evaporation Effects 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
125000003386 piperidinyl group Chemical group 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 8
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
235000019270 ammonium chloride Nutrition 0.000 description 8
239000012267 brine Substances 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 8
239000013078 crystal Substances 0.000 description 8
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 8
238000001914 filtration Methods 0.000 description 8
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 8
125000000719 pyrrolidinyl group Chemical group 0.000 description 8
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 7
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
125000003545 alkoxy group Chemical group 0.000 description 7
125000006606 n-butoxy group Chemical group 0.000 description 7
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 6
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 6
238000001816 cooling Methods 0.000 description 6
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
238000001035 drying Methods 0.000 description 6
125000005843 halogen group Chemical group 0.000 description 6
229940049953 phenylacetate Drugs 0.000 description 6
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 6
238000002953 preparative HPLC Methods 0.000 description 6
125000003831 tetrazolyl group Chemical group 0.000 description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
125000003806 alkyl carbonyl amino group Chemical group 0.000 description 5
239000013058 crude material Substances 0.000 description 5
125000002541 furyl group Chemical group 0.000 description 5
239000011777 magnesium Substances 0.000 description 5
229910052749 magnesium Inorganic materials 0.000 description 5
229910052943 magnesium sulfate Inorganic materials 0.000 description 5
235000019341 magnesium sulphate Nutrition 0.000 description 5
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
125000000168 pyrrolyl group Chemical group 0.000 description 5
125000001544 thienyl group Chemical group 0.000 description 5
ONWGSWNHQZYCFK-UHFFFAOYSA-N 2-(bromomethyl)-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(CBr)=C1 ONWGSWNHQZYCFK-UHFFFAOYSA-N 0.000 description 4
208000030507 AIDS Diseases 0.000 description 4
102000019034 Chemokines Human genes 0.000 description 4
108010012236 Chemokines Proteins 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
229910052786 argon Inorganic materials 0.000 description 4
208000010668 atopic eczema Diseases 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
125000000068 chlorophenyl group Chemical group 0.000 description 4
239000012043 crude product Substances 0.000 description 4
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 4
125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 4
IIFCLXHRIYTHPV-UHFFFAOYSA-N methyl 2,4-dihydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C=C1O IIFCLXHRIYTHPV-UHFFFAOYSA-N 0.000 description 4
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 4
125000002757 morpholinyl group Chemical group 0.000 description 4
239000012071 phase Substances 0.000 description 4
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000000843 powder Substances 0.000 description 4
125000004076 pyridyl group Chemical group 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
210000002345 respiratory system Anatomy 0.000 description 4
239000002002 slurry Substances 0.000 description 4
238000000859 sublimation Methods 0.000 description 4
230000008022 sublimation Effects 0.000 description 4
VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
DYQAWFUHUWWRIX-UHFFFAOYSA-N 1-benzyl-4-[(2,5-difluorophenyl)methyl]piperidin-4-ol Chemical compound C1CN(CC=2C=CC=CC=2)CCC1(O)CC1=CC(F)=CC=C1F DYQAWFUHUWWRIX-UHFFFAOYSA-N 0.000 description 3
DJXBUSVMEONVRS-UHFFFAOYSA-N 2-(bromomethyl)-4-chloro-1-fluorobenzene Chemical compound FC1=CC=C(Cl)C=C1CBr DJXBUSVMEONVRS-UHFFFAOYSA-N 0.000 description 3
SVDDJQGVOFZBNX-UHFFFAOYSA-N 2-chloroethyl carbonochloridate Chemical compound ClCCOC(Cl)=O SVDDJQGVOFZBNX-UHFFFAOYSA-N 0.000 description 3
XXYNZSATHOXXBJ-UHFFFAOYSA-N 4-hydroxyisoindole-1,3-dione Chemical compound OC1=CC=CC2=C1C(=O)NC2=O XXYNZSATHOXXBJ-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
125000003282 alkyl amino group Chemical group 0.000 description 3
125000004448 alkyl carbonyl group Chemical group 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
229960001701 chloroform Drugs 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 3
125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 3
239000003480 eluent Substances 0.000 description 3
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
125000001041 indolyl group Chemical group 0.000 description 3
125000000842 isoxazolyl group Chemical group 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
SWKKKZKIPZOMBG-UHFFFAOYSA-N methyl 3-nitrobenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 SWKKKZKIPZOMBG-UHFFFAOYSA-N 0.000 description 3
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 3
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
125000004193 piperazinyl group Chemical group 0.000 description 3
125000003367 polycyclic group Chemical group 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
125000003226 pyrazolyl group Chemical group 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
125000003003 spiro group Chemical group 0.000 description 3
239000007858 starting material Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
125000001113 thiadiazolyl group Chemical group 0.000 description 3
125000001984 thiazolidinyl group Chemical group 0.000 description 3
125000000335 thiazolyl group Chemical group 0.000 description 3
125000004568 thiomorpholinyl group Chemical group 0.000 description 3
125000001425 triazolyl group Chemical group 0.000 description 3
BUXYPPMJWUXVBV-UHFFFAOYSA-N (4-acetamido-3-hydroxyphenyl) acetate Chemical compound CC(=O)NC1=CC=C(OC(C)=O)C=C1O BUXYPPMJWUXVBV-UHFFFAOYSA-N 0.000 description 2
MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
NWJSQYDYACROJZ-UHFFFAOYSA-N 1-benzyl-3-[(5-chloro-2-fluorophenyl)methyl]pyrrolidin-3-ol Chemical compound C1CN(CC=2C=CC=CC=2)CC1(O)CC1=CC(Cl)=CC=C1F NWJSQYDYACROJZ-UHFFFAOYSA-N 0.000 description 2
WMUQWAIHTZUAFE-UHFFFAOYSA-N 1-benzyl-4-[(2-fluoro-5-methylphenyl)methyl]piperidin-4-ol Chemical compound CC1=CC=C(F)C(CC2(O)CCN(CC=3C=CC=CC=3)CC2)=C1 WMUQWAIHTZUAFE-UHFFFAOYSA-N 0.000 description 2
SULYEHHGGXARJS-UHFFFAOYSA-N 2',4'-dihydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1O SULYEHHGGXARJS-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
NWULWVPYPIRXAU-UHFFFAOYSA-N 2-hydroxy-3-methylbenzamide Chemical compound CC1=CC=CC(C(N)=O)=C1O NWULWVPYPIRXAU-UHFFFAOYSA-N 0.000 description 2
RZKJWYDRDBVDJJ-UHFFFAOYSA-N 2-methyl-1,3-benzoxazol-6-ol Chemical compound C1=C(O)C=C2OC(C)=NC2=C1 RZKJWYDRDBVDJJ-UHFFFAOYSA-N 0.000 description 2
BYDRTKVGBRTTIT-UHFFFAOYSA-N 2-methylprop-2-en-1-ol Chemical compound CC(=C)CO BYDRTKVGBRTTIT-UHFFFAOYSA-N 0.000 description 2
FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
MDYYZYITHXRIDA-UHFFFAOYSA-N 3-cyclopropyl-2-hydroxybenzamide Chemical compound NC(=O)C1=CC=CC(C2CC2)=C1O MDYYZYITHXRIDA-UHFFFAOYSA-N 0.000 description 2
ASHGTJPOSUFTGB-UHFFFAOYSA-N 3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1 ASHGTJPOSUFTGB-UHFFFAOYSA-N 0.000 description 2
MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 2
RZIYWKZWSSFEFI-UHFFFAOYSA-N 4-o-tert-butyl 2-o-methyl morpholine-2,4-dicarboxylate Chemical compound COC(=O)C1CN(C(=O)OC(C)(C)C)CCO1 RZIYWKZWSSFEFI-UHFFFAOYSA-N 0.000 description 2
ONMOULMPIIOVTQ-UHFFFAOYSA-N 98-47-5 Chemical compound OS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 ONMOULMPIIOVTQ-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
201000008283 Atrophic Rhinitis Diseases 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
241000721454 Pemphigus Species 0.000 description 2
206010039088 Rhinitis atrophic Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
102100029645 UBX domain-containing protein 11 Human genes 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
125000002723 alicyclic group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
239000003637 basic solution Substances 0.000 description 2
ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
229960002130 benzoin Drugs 0.000 description 2
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
239000002975 chemoattractant Substances 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 2
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
238000011097 chromatography purification Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
201000009151 chronic rhinitis Diseases 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
235000008504 concentrate Nutrition 0.000 description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000013504 emergency use authorization Methods 0.000 description 2
AGGMUFZXAAWSSV-UHFFFAOYSA-N ethyl 1-benzyl-4-[(2-fluorophenyl)methyl]piperidine-4-carboxylate Chemical compound C1CN(CC=2C=CC=CC=2)CCC1(C(=O)OCC)CC1=CC=CC=C1F AGGMUFZXAAWSSV-UHFFFAOYSA-N 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
125000001207 fluorophenyl group Chemical group 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
239000005457 ice water Substances 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
ZICRWXFGZCVTBZ-UHFFFAOYSA-N methyl 2-hydroxy-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C=C1O ZICRWXFGZCVTBZ-UHFFFAOYSA-N 0.000 description 2
YQCFUMFXEPULSH-UHFFFAOYSA-N methyl 2-hydroxy-4-trityloxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 YQCFUMFXEPULSH-UHFFFAOYSA-N 0.000 description 2
WPWUDDDJTIZBGL-UHFFFAOYSA-N methyl 4-fluoro-2-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(F)C=C1O WPWUDDDJTIZBGL-UHFFFAOYSA-N 0.000 description 2
FWVVYIBOMRGUOT-UHFFFAOYSA-N methyl 5-chloro-2,4-dihydroxybenzoate Chemical compound COC(=O)C1=CC(Cl)=C(O)C=C1O FWVVYIBOMRGUOT-UHFFFAOYSA-N 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
229960001047 methyl salicylate Drugs 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
239000012452 mother liquor Substances 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
238000005192 partition Methods 0.000 description 2
CKOOABJZYWLHMN-UHFFFAOYSA-N phenyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1=CC=CC=C1.C=1C=CC=CC=1C(=O)OC1=CC=CC=C1 CKOOABJZYWLHMN-UHFFFAOYSA-N 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
125000002098 pyridazinyl group Chemical group 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical class [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
QJIDMPVCOUCDTJ-UHFFFAOYSA-N tert-butyl 4-[(5-chloro-2-fluorophenyl)methyl]-3-fluoro-4-hydroxypiperidine-1-carboxylate Chemical compound FC1CN(C(=O)OC(C)(C)C)CCC1(O)CC1=CC(Cl)=CC=C1F QJIDMPVCOUCDTJ-UHFFFAOYSA-N 0.000 description 2
ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
UNROYLKRQDUXFX-UHFFFAOYSA-N (tert-butylazaniumyl)boron(1-) Chemical compound [B-][NH2+]C(C)(C)C UNROYLKRQDUXFX-UHFFFAOYSA-N 0.000 description 1
DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
CSCPPACGZOOCGX-KPAILUHGSA-N 1,1,1,3,3-pentadeuteriopropan-2-one Chemical compound [2H]C([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-KPAILUHGSA-N 0.000 description 1
LEEANUDEDHYDTG-UHFFFAOYSA-N 1,2-dimethoxypropane Chemical compound COCC(C)OC LEEANUDEDHYDTG-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
XTGCUDZCCIRWHL-UHFFFAOYSA-N 1-(5-chloro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(Cl)=CC=C1O XTGCUDZCCIRWHL-UHFFFAOYSA-N 0.000 description 1
FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
USIVMVHZRCKJGX-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;urea Chemical compound NC(N)=O.OC(=O)C(F)(F)F USIVMVHZRCKJGX-UHFFFAOYSA-N 0.000 description 1
SSZYZSRPAKZEIB-UHFFFAOYSA-N 2,3-dihydroxy-4-oxo-4-propan-2-yloxybutanoic acid Chemical compound CC(C)OC(=O)C(O)C(O)C(O)=O SSZYZSRPAKZEIB-UHFFFAOYSA-N 0.000 description 1
KZKVPZSPWVMNMC-UHFFFAOYSA-N 2-(hydroxymethyl)morpholine-4-carboxylic acid Chemical compound OCC1CN(C(O)=O)CCO1 KZKVPZSPWVMNMC-UHFFFAOYSA-N 0.000 description 1
SWFNPENEBHAHEB-UHFFFAOYSA-N 2-amino-4-chlorophenol Chemical compound NC1=CC(Cl)=CC=C1O SWFNPENEBHAHEB-UHFFFAOYSA-N 0.000 description 1
FZCQMIRJCGWWCL-UHFFFAOYSA-N 2-amino-5-chlorophenol Chemical compound NC1=CC=C(Cl)C=C1O FZCQMIRJCGWWCL-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
QLRKALMVPCQTMU-UHFFFAOYSA-N 2-bromo-1-fluoro-4-methylbenzene Chemical compound CC1=CC=C(F)C(Br)=C1 QLRKALMVPCQTMU-UHFFFAOYSA-N 0.000 description 1
YFFUYGSLQXVHMB-UHFFFAOYSA-N 2-bromo-4-chloro-1-fluorobenzene Chemical compound FC1=CC=C(Cl)C=C1Br YFFUYGSLQXVHMB-UHFFFAOYSA-N 0.000 description 1
USMQLFCVCDEXAK-UHFFFAOYSA-N 2-bromo-4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1Br USMQLFCVCDEXAK-UHFFFAOYSA-N 0.000 description 1
JIQXVIJARQLCOY-UHFFFAOYSA-N 2-bromo-4-fluoro-1-methoxybenzene Chemical compound COC1=CC=C(F)C=C1Br JIQXVIJARQLCOY-UHFFFAOYSA-N 0.000 description 1
RBCPJQQJBAQSOU-UHFFFAOYSA-N 2-bromo-5-chlorobenzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1Br RBCPJQQJBAQSOU-UHFFFAOYSA-N 0.000 description 1
OQBMJMJZMDBQSM-UHFFFAOYSA-N 2-bromo-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1Br OQBMJMJZMDBQSM-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
MNWSGMTUGXNYHJ-UHFFFAOYSA-N 2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(N)=O MNWSGMTUGXNYHJ-UHFFFAOYSA-N 0.000 description 1
ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 description 1
JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 1
LGWMTRPJZFEWCX-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOC(C(O)=O)C1 LGWMTRPJZFEWCX-UHFFFAOYSA-N 0.000 description 1
GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 description 1
IVFPOQYLPREKGF-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]sulfonylpiperidine;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(S(=O)(=O)C2CCNCC2)=C1 IVFPOQYLPREKGF-UHFFFAOYSA-N 0.000 description 1
WWOBYPKUYODHDG-UHFFFAOYSA-N 4-chlorocatechol Chemical compound OC1=CC=C(Cl)C=C1O WWOBYPKUYODHDG-UHFFFAOYSA-N 0.000 description 1
VNDHYTGVCGVETQ-UHFFFAOYSA-N 4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C=C1 VNDHYTGVCGVETQ-UHFFFAOYSA-N 0.000 description 1
QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 1
TVFGWSVHUUTITG-UHFFFAOYSA-N 5-fluorospiro[1,2-dihydroindole-3,4'-piperidine] Chemical compound C12=CC(F)=CC=C2NCC21CCNCC2 TVFGWSVHUUTITG-UHFFFAOYSA-N 0.000 description 1
NRTULWPODYLFOJ-UHFFFAOYSA-N 5-methoxy-2-nitrophenol Chemical compound COC1=CC=C([N+]([O-])=O)C(O)=C1 NRTULWPODYLFOJ-UHFFFAOYSA-N 0.000 description 1
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
208000035939 Alveolitis allergic Diseases 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
102100033891 Arylsulfatase I Human genes 0.000 description 1
206010003559 Asthma late onset Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
102000001902 CC Chemokines Human genes 0.000 description 1
108010040471 CC Chemokines Proteins 0.000 description 1
108050006947 CXC Chemokine Proteins 0.000 description 1
102000019388 CXC chemokine Human genes 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
241000611750 Coregonus kiyi Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012455 Dermatitis exfoliative Diseases 0.000 description 1
235000005459 Digitaria exilis Nutrition 0.000 description 1
206010014950 Eosinophilia Diseases 0.000 description 1
206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
102100023688 Eotaxin Human genes 0.000 description 1
101710139422 Eotaxin Proteins 0.000 description 1
206010014989 Epidermolysis bullosa Diseases 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
208000027445 Farmer Lung Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
101000925544 Homo sapiens Arylsulfatase I Proteins 0.000 description 1
101000595534 Homo sapiens Transforming growth factor beta regulator 1 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
102100026236 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
239000012448 Lithium borohydride Substances 0.000 description 1
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
102100036154 Platelet basic protein Human genes 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
235000010575 Pueraria lobata Nutrition 0.000 description 1
244000046146 Pueraria lobata Species 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
208000036284 Rhinitis seasonal Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
229910006351 Si—Sb Inorganic materials 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
244000028419 Styrax benzoin Species 0.000 description 1
235000000126 Styrax benzoin Nutrition 0.000 description 1
235000008411 Sumatra benzointree Nutrition 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
102100036078 Transforming growth factor beta regulator 1 Human genes 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
HDTDGVNYXDYKSO-JTQLQIEISA-N [(2s)-2-methyloxiran-2-yl]methyl 3-nitrobenzenesulfonate Chemical compound C=1C=CC([N+]([O-])=O)=CC=1S(=O)(=O)OC[C@]1(C)CO1 HDTDGVNYXDYKSO-JTQLQIEISA-N 0.000 description 1
RWPALELLYWNTCO-UHFFFAOYSA-N [1-benzyl-4-[(2-fluorophenyl)methyl]piperidin-4-yl]methanol Chemical compound C1CN(CC=2C=CC=CC=2)CCC1(CO)CC1=CC=CC=C1F RWPALELLYWNTCO-UHFFFAOYSA-N 0.000 description 1
XYMGFGLYSHSVHV-UHFFFAOYSA-N [3-(trifluoromethyl)pyrrolidin-3-yl] 2,2,2-trifluoroacetate Chemical compound FC(C(=O)OC1(CNCC1)C(F)(F)F)(F)F XYMGFGLYSHSVHV-UHFFFAOYSA-N 0.000 description 1
OMTTUAPWIJTTFJ-UHFFFAOYSA-N [I-].C[SH2+]=O Chemical compound [I-].C[SH2+]=O OMTTUAPWIJTTFJ-UHFFFAOYSA-N 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000036428 airway hyperreactivity Effects 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940047583 cetamide Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
208000017760 chronic graft versus host disease Diseases 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
108010035886 connective tissue-activating peptide Proteins 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
QUQFTIVBFKLPCL-UHFFFAOYSA-L copper;2-amino-3-[(2-amino-2-carboxylatoethyl)disulfanyl]propanoate Chemical compound [Cu+2].[O-]C(=O)C(N)CSSCC(N)C([O-])=O QUQFTIVBFKLPCL-UHFFFAOYSA-L 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
238000009509 drug development Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
125000006575 electron-withdrawing group Chemical group 0.000 description 1
201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
OBUNLFQVPAABFB-UHFFFAOYSA-N ethoxyethane;heptane Chemical compound CCOCC.CCCCCCC OBUNLFQVPAABFB-UHFFFAOYSA-N 0.000 description 1
OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
229950005098 ethoxzolamide Drugs 0.000 description 1
ASQCOPJFYLJCGD-UHFFFAOYSA-N ethyl 1-benzylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)CCN1CC1=CC=CC=C1 ASQCOPJFYLJCGD-UHFFFAOYSA-N 0.000 description 1
LUBGFMZTGFXIIN-UHFFFAOYSA-N ethyl 4-oxopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(=O)CC1 LUBGFMZTGFXIIN-UHFFFAOYSA-N 0.000 description 1
125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
125000006125 ethylsulfonyl group Chemical group 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000022195 farmer lung disease Diseases 0.000 description 1
238000003682 fluorination reaction Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
235000019382 gum benzoic Nutrition 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
125000004464 hydroxyphenyl group Chemical group 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
208000008585 mastocytosis Diseases 0.000 description 1
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
UITFCFWKYAOJEJ-UHFFFAOYSA-N methyl 2-hydroxy-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1O UITFCFWKYAOJEJ-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
108091074848 miR-19 stem-loop Proteins 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
KDFZHTZAGWNFHV-UHFFFAOYSA-N morpholin-2-ylmethyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OCC1CNCCO1 KDFZHTZAGWNFHV-UHFFFAOYSA-N 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
125000006137 n-hexyl sulfonyl group Chemical group 0.000 description 1
NCCHARWOCKOHIH-UHFFFAOYSA-N n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1 NCCHARWOCKOHIH-UHFFFAOYSA-N 0.000 description 1
125000006129 n-pentyl sulfonyl group Chemical group 0.000 description 1
125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
229930195143 oxyphenol Natural products 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
235000007715 potassium iodide Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000002994 raw material Substances 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
ZBYFQSPEUIVDTF-UHFFFAOYSA-N spiro[1,2-dihydroindene-3,4'-piperidine] Chemical compound C12=CC=CC=C2CCC21CCNCC2 ZBYFQSPEUIVDTF-UHFFFAOYSA-N 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
FJYBLMJHXRWDAQ-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC(CO)C1 FJYBLMJHXRWDAQ-UHFFFAOYSA-N 0.000 description 1
QAZYGHLQQPTQAX-UHFFFAOYSA-N tert-butyl 2-hydroxybenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1O QAZYGHLQQPTQAX-UHFFFAOYSA-N 0.000 description 1
JZNWQLLPLOQGOI-UHFFFAOYSA-N tert-butyl 3-fluoro-4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C(F)C1 JZNWQLLPLOQGOI-UHFFFAOYSA-N 0.000 description 1
LTDRQRZCMHBRKM-UHFFFAOYSA-N tert-butyl 3-hydroxy-3-(trifluoromethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)(C(F)(F)F)C1 LTDRQRZCMHBRKM-UHFFFAOYSA-N 0.000 description 1
WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
208000001319 vasomotor rhinitis Diseases 0.000 description 1
201000005539 vernal conjunctivitis Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

UA20041210166A 2002-07-08 2003-07-07 Tricyclic spiropiperidines or spiropyrrolidines, method for their synthesis (variants), use thereof, method for treating inflammations and respiratory diseases, pharmaceutical composition, intermediate, method for producing intermediate UA77809C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0202133A SE0202133D0 (sv)	2002-07-08	2002-07-08	Novel compounds
PCT/SE2003/001185 WO2004005295A1 (en)	2002-07-08	2003-07-07	Novel tricyclic spiropiperidines or spiropyrrolidines

Publications (1)

Publication Number	Publication Date
UA77809C2 true UA77809C2 (en)	2007-01-15

Family

ID=20288470

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20041210166A UA77809C2 (en)	2002-07-08	2003-07-07	Tricyclic spiropiperidines or spiropyrrolidines, method for their synthesis (variants), use thereof, method for treating inflammations and respiratory diseases, pharmaceutical composition, intermediate, method for producing intermediate

Country Status (25)

Country	Link
US (2)	US7449475B2 (de)
EP (1)	EP1521757B1 (de)
JP (1)	JP2005537255A (de)
CN (2)	CN1974574A (de)
AR (1)	AR040475A1 (de)
AT (1)	ATE385235T1 (de)
AU (1)	AU2003243122B2 (de)
BR (1)	BR0312560A (de)
CA (1)	CA2492122A1 (de)
CY (1)	CY1107915T1 (de)
DE (1)	DE60318948T2 (de)
DK (1)	DK1521757T3 (de)
ES (1)	ES2298575T3 (de)
IS (1)	IS7662A (de)
MX (1)	MXPA05000278A (de)
NO (1)	NO20050635L (de)
NZ (1)	NZ537259A (de)
PL (1)	PL374877A1 (de)
PT (1)	PT1521757E (de)
RU (1)	RU2320664C2 (de)
SE (1)	SE0202133D0 (de)
TW (1)	TW200413386A (de)
UA (1)	UA77809C2 (de)
WO (1)	WO2004005295A1 (de)
ZA (1)	ZA200500024B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0202133D0 (sv)	2002-07-08	2002-07-08	Astrazeneca Ab	Novel compounds
EP1661889A4 (de) *	2003-09-05	2009-08-05	Ono Pharmaceutical Co	Chemokinrezeptorantagonist und dessen medizinische verwendung
US20070021498A1 (en) *	2004-10-14	2007-01-25	Nafizal Hossain	Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
SE0302755D0 (sv) *	2003-10-17	2003-10-17	Astrazeneca Ab	Novel compounds
SE0302811D0 (sv) *	2003-10-23	2003-10-23	Astrazeneca Ab	Novel compounds
SE0303090D0 (sv) *	2003-11-20	2003-11-20	Astrazeneca Ab	Novel compounds
SE0303280D0 (sv) *	2003-12-05	2003-12-05	Astrazeneca Ab	Novel compounds
SE0303541D0 (sv) *	2003-12-22	2003-12-22	Astrazeneca Ab	New compounds
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
CA2570637A1 (en)	2004-06-24	2006-02-02	Wenqing Yao	N-substituted piperidines and their use as pharmaceuticals
EP1883402A2 (de)	2005-04-13	2008-02-06	Astex Therapeutics Limited	Hydroxybenzamidderivate und ihre verwendung als hsp90-inhibitoren
JP2009507800A (ja)	2005-09-09	2009-02-26	ユーロ−セルティークエス．エイ．	縮合およびスピロ環化合物ならびにその使用
JP5315590B2 (ja) *	2006-02-14	2013-10-16	Ｊｎｃ株式会社	液晶化合物、液晶組成物および液晶表示素子
US7754725B2 (en)	2006-03-01	2010-07-13	Astex Therapeutics Ltd.	Dihydroxyphenyl isoindolymethanones
TW200821316A (en) *	2006-07-19	2008-05-16	Astrazeneca Ab	Novel compounds 243
JP5528806B2 (ja)	2006-10-12	2014-06-25	アステックス、セラピューティックス、リミテッド	複合薬剤
WO2008044054A2 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Hydroxy-substituted benzoic acid amide compounds for use in therapy
EP2081891A2 (de)	2006-10-12	2009-07-29	Astex Therapeutics Limited	Pharmazeutische verbindungen mit hsp90-hemmender oder modulierender wirkung
JP5721949B2 (ja)	2006-10-12	2015-05-20	アステックス、セラピューティックス、リミテッドＡｓｔｅｘＴｈｅｒａｐｅｕｔｉｃｓＬｉｍｉｔｅｄ	複合薬剤
GB0620259D0 (en)	2006-10-12	2006-11-22	Astex Therapeutics Ltd	Pharmaceutical compounds
JP5528807B2 (ja)	2006-10-12	2014-06-25	アステックス、セラピューティックス、リミテッド	複合薬剤
US8012955B2 (en)	2006-12-28	2011-09-06	Rigel Pharmaceuticals, Inc.	N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
US20110124613A1 (en) *	2007-02-23	2011-05-26	Tomas Eriksson	Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
US20110136843A1 (en) *	2007-02-23	2011-06-09	Tomas Eriksson	Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
WO2008121066A1 (en) *	2007-03-30	2008-10-09	Astrazeneca Ab	Novel tricyclic spiropiperidines or spiropyrrolidines and their use as modulators of chemokine receptors
PE20090829A1 (es) *	2007-06-20	2009-07-25	Glaxo Group Ltd	Espiroindolinas como moduladores de receptores de quimioquinas
WO2009011655A1 (en) *	2007-07-17	2009-01-22	Astrazeneca Ab	Splropiperidine compounds, a process of their preparation, pharmaceutical compositions containing them, and their use in the treatment of airway diseases, inflammatory diseases, copd or asthma
WO2009011653A1 (en) *	2007-07-17	2009-01-22	Astrazeneca Ab	A process for the preparation of intermediates and their us in the synthesis of spiropiperidine compounds
CN101808990B (zh) *	2007-07-24	2012-09-05	百时美施贵宝公司	作为趋化因子受体活性调节剂的哌啶衍生物
EP2190286A4 (de) *	2007-08-14	2011-06-01	Glaxo Group Ltd	Spiroindene und spiroindane als modulatoren von chemokin-rezeptoren
WO2009061881A1 (en) *	2007-11-07	2009-05-14	Glaxo Group Limited	Spirodihydrobenzofurans as modulators of chemokine receptors
CA2712897A1 (en) *	2008-01-30	2009-08-06	Pharmacopeia, Inc.	Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
FR2928150A1 (fr)	2008-02-29	2009-09-04	Vetoquinol Sa Sa	Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
GB0806527D0 (en)	2008-04-11	2008-05-14	Astex Therapeutics Ltd	Pharmaceutical compounds
EP2145891A1 (de)	2008-07-09	2010-01-20	Vetoquinol S.A.	9-substierte 5-Carboxy-Oxadiazin-Chinolon-Derivate, ihre Herstellung und ihre Anwendung als antibakterielle Mittel
AR078948A1 (es) *	2009-11-30	2011-12-14	Lilly Co Eli	Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
US10633336B2 (en)	2014-12-19	2020-04-28	The Broad Institute, Inc.	Dopamine D2 receptor ligands
US10752588B2 (en)	2014-12-19	2020-08-25	The Broad Institute, Inc.	Dopamine D2 receptor ligands
EP3668840A1 (de)	2017-08-15	2020-06-24	Inflazome Limited	Neuartige sulfonamid-carboxamid-verbindungen
EP4093731A1 (de)	2020-01-20	2022-11-30	Neophore Limited	An eine atp-bindungsstelle bindende isoindolinderivate
GB202008201D0 (en) *	2020-06-01	2020-07-15	Neophore Ltd	Inhibitor compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4010201A (en)	1974-04-12	1977-03-01	The Upjohn Company	Organic compounds
US4166119A (en)	1978-04-14	1979-08-28	American Hoechst Corporation	Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4166120A (en) *	1978-04-14	1979-08-28	American Hoechst Corporation	Analgesic and tranquilizing benzoylpropyl-spiro[dihydrobenzofuran]piperidines and pyrrolidines
US4263317A (en)	1979-09-06	1981-04-21	Hoechst-Roussel Pharmaceuticals, Inc.	Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
US5366986A (en)	1988-04-15	1994-11-22	T Cell Sciences, Inc.	Compounds which inhibit complement and/or suppress immune activity
DE3930262A1 (de)	1989-09-11	1991-03-21	Thomae Gmbh Dr K	Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
NZ258412A (en) *	1992-12-11	1997-01-29	Merck & Co Inc	Spiro-fused piperidine derivatives and pharmaceutical compositions
DE69412067T2 (de) *	1993-01-28	1999-03-25	Merck & Co., Inc., Rahway, N.J.	Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
JPH09512016A (ja) *	1994-04-14	1997-12-02	メルクエンドカンパニーインコーポレーテッド	α１Ｃアドレナリン受容体拮抗薬
US5576321A (en)	1995-01-17	1996-11-19	Eli Lilly And Company	Compounds having effects on serotonin-related systems
DK0828728T3 (da)	1995-05-18	2003-05-19	Altana Pharma Ag	Phenyldihydrobenzofuraner
US5931917A (en) *	1996-09-26	1999-08-03	Verifone, Inc.	System, method and article of manufacture for a gateway system architecture with system administration information accessible from a browser
US5962462A (en)	1996-12-13	1999-10-05	Merck & Co., Inc.	Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5803398A (en) *	1996-12-13	1998-07-03	Merck & Co., Inc.	Spiro-substituted azacycles as modulators of chemokine receptor activity
CA2278309A1 (en) *	1997-01-21	1998-07-23	Merck & Co., Inc.	3,3-disubstituted piperidines as modulators of chemokine receptor activity
HUP0102404A2 (hu)	1998-02-04	2001-11-28	Banyu Pharmaceutical Co., Ltd.	N-acilezett gyűrűs aminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
US6151675A (en) *	1998-07-23	2000-11-21	Tumbleweed Software Corporation	Method and apparatus for effecting secure document format conversion
US6288083B1 (en) *	1998-09-04	2001-09-11	Millennium Pharmaceuticals, Inc.	Chemokine receptor antagonists and methods of use therefor
US6212640B1 (en) *	1999-03-25	2001-04-03	Sun Microsystems, Inc.	Resources sharing on the internet via the HTTP
US6226752B1 (en) *	1999-05-11	2001-05-01	Sun Microsystems, Inc.	Method and apparatus for authenticating users
AU1244001A (en)	1999-10-27	2001-05-08	Cor Therapeutics, Inc.	Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
WO2001064213A1 (en)	2000-03-02	2001-09-07	Smithkline Beecham Corporation	Compounds and methods
AR028948A1 (es)	2000-06-20	2003-05-28	Astrazeneca Ab	Compuestos novedosos
US7017175B2 (en) *	2001-02-02	2006-03-21	Opentv, Inc.	Digital television application protocol for interactive television
WO2002102387A1 (en)	2001-06-18	2002-12-27	H. Lundbeck A/S	Treatment of neuropathic pain
US20050143372A1 (en)	2001-10-30	2005-06-30	Shomir Ghosh	Compounds, pharmaceutical compositions and methods of use therefor
SE0202133D0 (sv)	2002-07-08	2002-07-08	Astrazeneca Ab	Novel compounds
JP2006511500A (ja)	2002-10-30	2006-04-06	メルク　エンド　カムパニー　インコーポレーテッド	γ−アミノアミド系のケモカイン受容体活性調節剤
CA2507501C (en)	2002-11-27	2011-10-04	Incyte Corporation	3-aminopyrrolidine derivatives as modulators of chemokine receptors
WO2004051453A1 (en) *	2002-12-04	2004-06-17	Entriq Inc.	Multiple content provider user interface
US7966418B2 (en) *	2003-02-21	2011-06-21	Axeda Corporation	Establishing a virtual tunnel between two computer programs
US20070021498A1 (en)	2004-10-14	2007-01-25	Nafizal Hossain	Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
SE0302755D0 (sv)	2003-10-17	2003-10-17	Astrazeneca Ab	Novel compounds
SE0302811D0 (sv)	2003-10-23	2003-10-23	Astrazeneca Ab	Novel compounds
SE0303090D0 (sv)	2003-11-20	2003-11-20	Astrazeneca Ab	Novel compounds
SE0303280D0 (sv)	2003-12-05	2003-12-05	Astrazeneca Ab	Novel compounds
SE0303541D0 (sv)	2003-12-22	2003-12-22	Astrazeneca Ab	New compounds
WO2005092858A2 (en)	2004-03-29	2005-10-06	Pfizer Japan Inc.	Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist

2002
- 2002-07-08 SE SE0202133A patent/SE0202133D0/xx unknown
2003
- 2003-07-03 TW TW092118200A patent/TW200413386A/zh unknown
- 2003-07-07 DE DE60318948T patent/DE60318948T2/de not_active Expired - Fee Related
- 2003-07-07 DK DK03762957T patent/DK1521757T3/da active
- 2003-07-07 PT PT03762957T patent/PT1521757E/pt unknown
- 2003-07-07 MX MXPA05000278A patent/MXPA05000278A/es active IP Right Grant
- 2003-07-07 US US10/520,699 patent/US7449475B2/en not_active Expired - Fee Related
- 2003-07-07 UA UA20041210166A patent/UA77809C2/uk unknown
- 2003-07-07 BR BR0312560-2A patent/BR0312560A/pt not_active IP Right Cessation
- 2003-07-07 AT AT03762957T patent/ATE385235T1/de not_active IP Right Cessation
- 2003-07-07 RU RU2004137278/04A patent/RU2320664C2/ru not_active IP Right Cessation
- 2003-07-07 CN CNA2006101435561A patent/CN1974574A/zh active Pending
- 2003-07-07 JP JP2004519472A patent/JP2005537255A/ja active Pending
- 2003-07-07 CA CA002492122A patent/CA2492122A1/en not_active Abandoned
- 2003-07-07 PL PL03374877A patent/PL374877A1/xx not_active Application Discontinuation
- 2003-07-07 EP EP03762957A patent/EP1521757B1/de not_active Expired - Lifetime
- 2003-07-07 CN CNB038191466A patent/CN1326858C/zh not_active Expired - Fee Related
- 2003-07-07 NZ NZ537259A patent/NZ537259A/en unknown
- 2003-07-07 ES ES03762957T patent/ES2298575T3/es not_active Expired - Lifetime
- 2003-07-07 AU AU2003243122A patent/AU2003243122B2/en not_active Ceased
- 2003-07-07 WO PCT/SE2003/001185 patent/WO2004005295A1/en not_active Ceased
- 2003-07-08 AR AR20030102463A patent/AR040475A1/es not_active Application Discontinuation
2005
- 2005-01-03 ZA ZA200500024A patent/ZA200500024B/xx unknown
- 2005-01-24 IS IS7662A patent/IS7662A/is unknown
- 2005-02-04 NO NO20050635A patent/NO20050635L/no not_active Application Discontinuation
2008
- 2008-04-03 CY CY20081100375T patent/CY1107915T1/el unknown
- 2008-11-05 US US12/265,251 patent/US20090062322A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2298575T3 (es)	2008-05-16
TW200413386A (en)	2004-08-01
ZA200500024B (en)	2006-02-22
CN1974574A (zh)	2007-06-06
CN1675218A (zh)	2005-09-28
CN1326858C (zh)	2007-07-18
US7449475B2 (en)	2008-11-11
JP2005537255A (ja)	2005-12-08
PT1521757E (pt)	2008-04-03
US20050245741A1 (en)	2005-11-03
NZ537259A (en)	2006-08-31
ATE385235T1 (de)	2008-02-15
US20090062322A1 (en)	2009-03-05
AU2003243122A1 (en)	2004-01-23
DK1521757T3 (da)	2008-05-05
RU2320664C2 (ru)	2008-03-27
MXPA05000278A (es)	2005-03-31
WO2004005295A1 (en)	2004-01-15
AR040475A1 (es)	2005-04-06
EP1521757B1 (de)	2008-01-30
AU2003243122B2 (en)	2006-09-28
RU2004137278A (ru)	2005-09-10
NO20050635L (no)	2005-03-31
PL374877A1 (en)	2005-11-14
EP1521757A1 (de)	2005-04-13
SE0202133D0 (sv)	2002-07-08
HK1074622A1 (en)	2005-11-18
IS7662A (is)	2005-01-24
CA2492122A1 (en)	2004-01-15
BR0312560A (pt)	2005-05-10
DE60318948D1 (de)	2008-03-20
DE60318948T2 (de)	2009-05-20
CY1107915T1 (el)	2013-09-04

Publication	Publication Date	Title
UA77809C2 (en)	2007-01-15	Tricyclic spiropiperidines or spiropyrrolidines, method for their synthesis (variants), use thereof, method for treating inflammations and respiratory diseases, pharmaceutical composition, intermediate, method for producing intermediate
AU2017294231B2 (en)	2021-09-09	Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
EP3686196B1 (de)	2024-06-12	Polyzyklische verbindung als ido-inhibitor und/oder ido-hdac-doppelinhibitor
CN109496213B (zh)	2022-03-04	螺环化合物及其制备和使用方法
JP2008179621A (ja)	2008-08-07	含窒素飽和複素環化合物
CA2891574A1 (en)	2014-05-22	Dihydropyrazole gpr40 modulators
CN111217802B (zh)	2021-10-08	一类组蛋白乙酰化酶p300抑制剂及其用途
JP2017514856A (ja)	2017-06-08	糖尿病などの疾患の治療用のピロリジンｇｐｒ４０モジュレータ
EP2602248A1 (de)	2013-06-12	Neue Pyrrol Verbindungen
US7498338B2 (en)	2009-03-03	Compounds
Stecko et al.	2006	Double asymmetric induction in 1, 3-dipolar cycloaddition of five-membered cyclic nitrones to 2-(5H)-furanones
EP1847535A1 (de)	2007-10-24	1-(piperidin-4-yl)-1h-indolderivate
WO2025067239A1 (zh)	2025-04-03	驱动蛋白kif18a抑制剂及其应用
TW202545534A (zh)	2025-12-01	Ｂｃｌ－２抑制劑
CN101184749B (zh)	2012-12-05	螺环杂环衍生物及其使用方法
HK1074622B (en)	2008-06-13	Tricyclic spiropiperidines or spiropyrrolidines
TW202530205A (zh)	2025-08-01	經取代之芳基磺醯胺及其組合物及用途
KR20050017096A (ko)	2005-02-21	신규한 트리시클릭 스피로피페리딘 또는 스피로피롤리딘
HK40004417A (en)	2020-04-24	Spirocycle compounds and methods of making and using same
MXPA06005427A (en)	2006-10-17	Novel compounds